Antihemophilic factor (AHF, Factor VIII) antigen has been demonstrated in cultured human endothelial cells by immunofluorescence studies using monospecific rabbit antibody to human AHF. Control studies with cultured human smooth muscle cells and human fibroblasts were negative. By radioimmunoassay it was demonstrated that cultured human endothelial cells contain AHF antigen which is released into the culture medium. Cultured smooth muscle cells and fibroblasts did not have this property. Cultured endothelial cells incorporated radioactive amino acids into high molecular weight, AHF antigen-rich protein fractions prepared from the culture media, 7% of the radioactive amino acid counts incorporated into this material were precipitated by globulin prepared from rabbit anti-AHF whereas normal rabbit globulin precipitated only 1.5% of the counts. Although cultured endothelial cells actively synthesize AHF antigen, AHF procoagulant activity was not detected in the culture medium. Studies seeking a basis for the lack of procoagulant activity have not clarified this deficiency, but they have established that exogenous AHF procoagulant activity is not inactivated by the tissue culture system.
Eric A. Jaffe, Leon W. Hoyer, Ralph L. Nachman
Year: | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1984 | 1983 | 1982 | 1981 | 1980 | 1979 | 1978 | 1977 | 1976 | 1975 | 1974 | 1973 | 1968 | 1965 | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Citations: | 3 | 5 | 4 | 3 | 4 | 2 | 3 | 8 | 6 | 3 | 6 | 11 | 7 | 3 | 9 | 10 | 5 | 9 | 7 | 7 | 6 | 14 | 19 | 19 | 18 | 27 | 17 | 24 | 28 | 39 | 37 | 45 | 40 | 51 | 39 | 60 | 57 | 46 | 46 | 47 | 29 | 37 | 25 | 26 | 26 | 19 | 10 | 22 | 5 | 2 | 1 | 1 | 997 |
Title and authors | Publication | Year |
---|---|---|
No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance
DJ Groeneveld, T Bekkum, KL Cheung, RJ Dirven, G Castaman, PH Reitsma, B Vlijmen, J Eikenboom |
Journal of Thrombosis and Haemostasis | 2015 |
The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies
Q Shi, JA Schroeder, EL Kuether, RR Montgomery |
Journal of Thrombosis and Haemostasis | 2015 |
von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease
YV Sanders, D Groeneveld, K Meijer, K Fijnvandraat, MH Cnossen, JG van der Bom, M Coppens, J Meris, BA Gorkom, EP Mauser-Bunschoten, FW Leebeek, J Eikenboom |
Blood | 2015 |
Chronic Renal Disease
P Delanaye, AD Rule |
2015 | |
Reduction of translation rate stabilizes circadian rhythm and reduces the magnitude of phase shift
M Nakajima, S Koinuma, Y Shigeyoshi |
Biochemical and Biophysical Research Communications | 2015 |
Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease
J Chen, JD Hinckley, S Haberichter, P Jacobi, R Montgomery, VH Flood, R Wong, G Interlandi, DW Chung, JA Lopez, JD Paola |
Blood | 2015 |
von Willebrand factor propeptide: biology and clinical utility
SL Haberichter |
Blood | 2015 |
PanVascular Medicine
AN Rizzo, DR Fraidenburg, JX Yuan |
PanVascular Medicine | 2015 |